Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.
Cholangiocarcinoma
DRUG: Durvalumab 1120 mg|DRUG: Durvalumab 1500 mg|DRUG: Tremelimumab i.v. at 300 mg|COMBINATION_PRODUCT: Cisplatin (CDDP) 25 mg/mq i.v|COMBINATION_PRODUCT: Gemcitabine (GEM) 1000 mg/mq i.v.
Recurrence rate of CCA, To determine whether neoadjuvant chemo- and immunotherapy decrease the recurrence rate of CCA at 12 months after surgery., 24 months
Rate of R0 resections, Rate of R0 resections (number of resections with surgical margins free from cancer/total number of resections) as assessed by pathologic examination (R1: microscopic disease., 24 months|Radiologic responses, Radiologic responses evaluated through the RECIST v1.1 criteria., 24 months|Pathologic responses, Pathologic responses (number of surgically removed tumour specimens with absence of any residual viable neoplastic cells)., 24 months|Toxicity assessed, Toxicity assessed by the NCI CTCAE v5.0, 24 months|PFS, Progression free survival (PFS) measured from study enrolment to death, 24 months|OS, Overall survival (OS) measured from study enrolment to death, 24 months
Exploratory objectives, Characterization of tumor microenvironment of primary CCAs and eventually resected metastases treated with neoadjuvant sequential chemo-immuno-therapy, 24 months|Exploratory objectives, Depiction of mutational evolution of CCA through NGS (Next Generation Sequencing) gene analysis on primary tumor biopsies and matched metastases (FFPE tissues or liquid biopsies)., 24 months
Multicenter, single arm, phase II study